Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAligos Therapeutics Inc

Aligos Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.16 USD -0.41 ( 15.95%)
Last update at 2026-11-11T21:00:00Z
VOLUME
282722
Market Cap
40.28M

Momentum Score

…

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.03
Low
2.81
High
52 Week Price Range
4.20
Low
13.69
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Aligos Therapeutics is a clinical-stage biopharmaceutical company developing antiviral therapies for chronic hepatitis B and other liver diseases. Long-term growth drivers include clinical progress, demonstration of safety and efficacy in key trials, and potential partnerships, which may benefit investors seeking exposure to therapies addressing unmet HBV needs.
Material risks are binary clinical and regulatory outcomes, ongoing financing needs, and intense competition from larger and emerging HBV developers; investors should monitor trial readouts and cash runway.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.57
Dividend Yield
-
Revenue TTM
2.19M
Revenue Per Share
0.22
Gross Profit TTM
-67.27M
Debt / Equity
0.10
ROE
-196.92%
Net Debt
-13.05M
ROCE
-130.74%
Diluted EPS TTM
-2.45

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -23.88M -130.88M -86.88M -95.94M -128.19M
Net income -24.19M -131.21M -87.68M -96.05M -128.33M
Selling general administrative 20.72M 22.83M 30.62M 26.41M 28.53M
Selling and marketing expenses - - 3.77M - -
Gross profit 1.26M 3.94M 15.53M 13.91M 4.36M
Reconciled depreciation 2.81M 2.62M 3.07M 3.67M 3.78M
Ebit -87.98M -89.15M -88.13M -101.25M -132.10M
Ebitda -87.06M -86.53M -85.06M -97.58M -128.32M
Depreciation and amortization 0.93M 2.62M 3.07M 3.67M 3.78M
Non operating income net other - - - -0.06M -0.11M
Operating income -87.98M -89.15M -88.13M -97.58M -128.32M
Other operating expenses 90.17M 93.10M 103.66M 111.49M 132.68M
Interest expense - - - 1.64M 0.13M
Tax provision 0.31M 0.33M 0.80M 0.11M 0.14M
Interest income - - 1.24M 1.64M 0.13M
Net interest income 3.92M 4.41M 1.24M 1.64M 0.13M
Income tax expense 0.31M 0.33M 0.80M 0.11M 0.14M
Total revenue 2.19M 3.94M 15.53M 13.91M 4.36M
Total operating expenses 89.24M 93.10M 103.66M 111.49M 132.68M
Cost of revenue 0.93M 2.62M 3.07M - -
Total other income expense net 64.11M -41.73M 1.24M 1.64M 0.13M
Net income from continuing ops -24.19M -131.21M -87.68M -96.05M -128.33M
Net income applicable to common shares - - - -96.05M -128.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 88.53M 70.09M 153.90M 146.69M 235.37M
Other current assets 5.02M 5.20M 5.31M 7.72M 13.69M
Total liab 34.99M 99.07M 61.82M 42.79M 50.64M
Total stockholder equity 53.55M -28.97M 92.08M 103.90M 184.73M
Other current liab 13.53M 15.56M 16.84M 16.04M 25.39M
Common stock 0.01M 0.01M 0.01M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.00M 0.00M
Retained earnings -642.20M -618.01M -486.80M -399.12M -303.07M
Other liab - - - 0.23M 0.13M
Other assets - - 0.00M 0.63M 0.87M
Cash 18.30M 37.00M 135.77M 81.35M 186.82M
Total current liabilities 21.23M 21.74M 23.91M 33.13M 38.96M
Current deferred revenue - 0.15M 1.31M 9.21M 7.64M
Net debt -13.05M -28.62M -124.64M -68.77M -172.36M
Short term debt 3.73M 3.46M 3.24M 3.14M 2.91M
Short long term debt total 5.25M 8.38M 11.14M 12.57M 14.46M
Other stockholder equity 695.27M 588.58M 578.33M 355.92M 251.98M
Property plant equipment - - - 4.82M 14.97M
Total current assets 82.86M 62.14M 141.08M 133.54M 204.42M
Long term investments - - - 0.00M 15.11M
Net tangible assets - - - 103.90M 184.73M
Short term investments 59.54M 19.94M 0.00M 44.48M 3.92M
Accounts payable 3.98M 2.57M 2.52M 4.74M 3.02M
Accumulated other comprehensive income 0.47M 0.45M 0.55M 0.40M 0.45M
Common stock total equity - - - 0.00M 0.00M
Retained earnings total equity - - - -399.12M -303.07M
Non currrent assets other 0.71M 0.63M 0.62M 0.63M 0.87M
Non current assets total 5.67M 7.95M 12.82M 13.15M 30.95M
Capital lease obligations 5.25M 8.38M 11.14M 12.57M 14.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -37.39M -18.28M 44.98M -25.35M 3.91M
Change to liabilities - - - -5.05M -4.67M
Total cashflows from investing activities -37.83M -18.28M 44.98M -26.29M 3.02M
Net borrowings -0.01M -0.08M -0.10M -0.06M -0.08M
Total cash from financing activities 101.64M 0.35M 88.33M 0.16M 78.68M
Change to operating activities - - - -5.78M 0.02M
Net income -24.19M -131.21M -87.68M -96.05M -128.33M
Change in cash -18.69M -98.67M 54.31M -105.52M -33.96M
Begin period cash flow 37.11M 135.77M 81.46M 186.98M 220.94M
End period cash flow 18.41M 37.11M 135.77M 81.46M 186.98M
Total cash from operating activities -82.50M -80.74M -79.00M -79.39M -115.66M
Issuance of capital stock 101.34M 0.00M 17.44M 0.00M 78.58M
Depreciation 0.93M 2.62M 3.07M 3.67M 3.78M
Sale purchase of stock - - - 0.23M 79.63M
Other cashflows from financing activities 101.64M 0.44M 70.98M 0.20M 0.17M
Change to netincome - - - 14.69M 13.54M
Capital expenditures 0.44M 0.13M 0.02M 0.94M 0.89M
Cash flows other operating - - - 4.87M -13.08M
Cash and cash equivalents changes - - - -105.52M -33.96M
Change in working capital -3.79M -4.96M -9.53M -1.55M -4.65M
Stock based compensation 5.04M 8.45M 12.65M 14.69M 13.46M
Other non cash items -60.50M 44.35M 2.49M -0.16M 0.09M
Free cash flow -82.94M -80.87M -79.02M -80.33M -116.55M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ALGS
Aligos Therapeutics Inc		 -0.41
15.95%		 2.16 - - 18.43 0.77 0.48 0.57
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

One Corporate Drive, South San Francisco, CA, United States, 94080

800 466 6059

https://www.aligos.com

82

Name Title Year Born
Dr. Lawrence M. Blatt MBA, Ph.D. CEO & Chairman 1962
Dr. Leonid Beigelman Ph.D. Pres & Director 1959
Dr. Julian A. Symons DPHIL Exec. VP & Chief Scientific Officer 1961
Ms. Lesley Ann Calhoun CPA Exec. VP & CFO 1966
Ms. Lucinda Y. Quan J.D. Exec. VP, Chief Bus. Officer & Gen. Counsel 1972
Kristina Engeseth Exec. Director and Head of People & Culture NA
Mr. John Fry Exec. VP of Clinical Devel. 1963
Dr. Matthew W. McClure M.D. Exec. VP & Chief Medical Officer 1972
Dr. Sushmita M. Chanda DABT, Ph.D. Exec. VP of Translational Safety Sciences 1966
Dr. David B. Smith Ph.D. Exec. VP & Head of Chemical Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…